European Union - English - EMA (European Medicines Agency)

allergan pharmaceuticals international ltd - pancreas powder - exocrine pancreatic insufficiency - digestives, incl. enzymes - pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer).enzepi is indicated in infants, children, adolescents and adults.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - pancreas powder ph. eur. - gastro-resistant capsule, hard - 20000 - multienzymes (lipase, protease etc.)

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - pancreas powder ph. eur. - gastro-resistant capsule, hard - 35000 - multienzymes (lipase, protease etc.)

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - pancreas powder ph. eur. - gastro-resistant capsule, hard - multienzymes (lipase, protease etc.)

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - pancreas powder ph. eur. - gastro-resistant capsule, hard - multienzymes (lipase, protease etc.)

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - pancreas powder - capsule, coated pellets - 150mg - pancreas powder 150mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methylprednisolone sodium succinate, quantity: 1.326 g (equivalent: methylprednisolone, qty 1 g) - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium hydroxide - when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, solu-medrol powder for injection is indicated only for intravenous or intramuscular use in the following conditions:,endocrine disorders,? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).,? acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used).,? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.,? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.,? c

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - olanzapine 10mg (there is a 10% overfill of powder) - powder for injection - 10 mg - active: olanzapine 10mg (there is a 10% overfill of powder) excipient: lactose monohydrate tartaric acid sodium chloride water for injection - zyprexa im is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia and related psychoses and in patients with acute mania associated with bipolar i disorder, when oral therapy is not appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.